Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

NCT ID: NCT01163032

Last Updated: 2014-10-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 136 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-08-31
• Study Completion Date: 2012-11-30

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder

Detailed Description

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals, primarily those without light perception, are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier if < 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping.

This will be a multicenter, randomized, double-masked, placebo-controlled, parallel study. The study has two phases: the pre-randomization phase followed by either the randomization phase or the open-label extension (OLE). The pre-randomization phase comprises a screening visit where subject's initial eligibility will be evaluated, a circadian period (τ) estimation segment, and a variable-length in-phase transition segment in which subjects will wait to start treatment until their circadian phase is aligned with their target bedtime. Subjects that meet all entry criteria for the study will enter the randomization phase. During the randomization phase, subjects will be asked to take either 20 mg tasimelteon or placebo approximately 1 hour prior to their target bedtime for 26 weeks in a double-masked fashion. Subjects who have a τ greater than 24.0 and meet all entry criteria but that are ineligible for the randomization phase due to their τ estimate may be given the opportunity to participate in the OLE phase. During the OLE phase, subjects will take open-label 20mg tasimelteon for 26 weeks.

Conditions

Non-24-Hour Sleep-Wake Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

tasimelteon

20 mg tasimelteon capsules, PO daily for 6 months

Group Type: EXPERIMENTAL

tasimelteon

Intervention Type: DRUG

20 mg tasimelteon capsules, PO daily for 6 months

placebo

Placebo capsules, PO daily for 6 months

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo capsules, PO daily for 6 months

Interventions

tasimelteon

20 mg tasimelteon capsules, PO daily for 6 months

Intervention Type: DRUG

Placebo

Placebo capsules, PO daily for 6 months

Intervention Type: DRUG

Other Intervention Names

VEC-162

Eligibility Criteria

Inclusion Criteria

• Ability and acceptance to provide informed consent;
• No perception of light by the subject's own report;
• Diagnosis of N24HSWD as determined by:

1. History (within the last 3 months) of trouble sleeping at night difficulty initiating sleep or staying asleep), difficulty awakening in the morning, or daytime sleepiness as determined by answering yes to at least one question in the Sleep Complaint Questionnaire and

2. Urinary aMT6s demonstrates a progressive delay of the aMT6 acrophase time.

• Willing and able to comply with study requirements and restrictions including a commitment to a fixed 9-hour sleep opportunity during the study;
• Fluent in English;

Exclusion Criteria

• Have a probable diagnosis of a current sleep disorder other than N24HSWD that is the primary cause of the sleep disturbance based on clinical investigator medical judgment;
• Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;
• History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;
• History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;
• Worked night, rotating, or split (period of work, followed by break, and then return to work) shift work within 1 month of the screening visit or plan to work these shifts during the study;
• Unable to perform calls to the study IVR system to report questionnaire results;
• Exposure to any investigational drug, including placebo, within 30 days or 5 half lives (whichever was longer) of screening;
• Use of central nervous system prescription or OTC medications, other than melatonin, that affects the sleep-wake cycle
• Use of melatonin or melatonin agonist

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vanda Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Vanda Pharmaceuticals

Role: STUDY_DIRECTOR

Vanda Pharmaceuticals

Locations

Pulmonary Associates, PA

Phoenix, Arizona, United States

SDS Clinical Trials Inc.

Orange, California, United States

VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)

Palo Alto, California, United States

St. Johns Sleep Disorder Center - St. Johns Medical Plaza

Santa Monica, California, United States

Radiant Research - Denver

Denver, Colorado, United States

PAB Clinical Research Inc.

Brandon, Florida, United States

Kendall South Medical Center, Inc.

Miami, Florida, United States

Ocean Sleep Disorders Center - Ormond Beach

Ormond Beach, Florida, United States

Sleep Disorders Center Of Georgia

Atlanta, Georgia, United States

Suburban Lung Associates SC (Chicago Metropolitan Area)

Elk Grove Village, Illinois, United States

The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)

Chevy Chase, Maryland, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Michigan Head-Pain Neurological Institute

Ann Arbor, Michigan, United States

St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)

Chesterfield, Missouri, United States

New York Eye and Ear Infirmary

New York, New York, United States

Tri-State Sleep Disorders Center

Cincinnati, Ohio, United States

Ohio Sleep Medicine Institute (Columbus Metropolitan Area)

Dublin, Ohio, United States

Lynn Health Science Institute

Oklahoma City, Oklahoma, United States

Columbia Research Group Inc.

Portland, Oregon, United States

Center For Sleep Medicine at Chestnut Hill Hospital

Philadelphia, Pennsylvania, United States

Consolidated Clinical trials

Pittsburgh, Pennsylvania, United States

SleepMed, Inc. - Columbia

Columbia, South Carolina, United States

Todd J. Swick, M.D., P.A.

Houston, Texas, United States

Advanced Sleep Research GmbH

Berlin, , Germany

Bergmannsheil University Hospital - Medical Clinic III

Bochum, , Germany

Klinische-Forschung Hannover Mitte

Hanover, , Germany

Universitaetsklinikum Glesen and Marburg gmbH/Schlaflabor - Sleep Lab University Marburg

Marburg, , Germany

Bonomed Studiezentrum

Munich, , Germany

Countries

United States; Germany

References

Lockley SW, Dressman MA, Licamele L, Xiao C, Fisher DM, Flynn-Evans EE, Hull JT, Torres R, Lavedan C, Polymeropoulos MH. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials. Lancet. 2015 Oct 31;386(10005):1754-64. doi: 10.1016/S0140-6736(15)60031-9. Epub 2015 Aug 4.

Reference Type: DERIVED

PMID: 26466871 (View on PubMed)

Other Identifiers

VP-VEC-162-3201

Identifier Type: -

Identifier Source: org_study_id